VIAVI Q1 FY27: Growth Decelerates, Non-GAAP Masking Continues

What happened

VIAVI reported fiscal Q1 2027 results that were superficially in line with prior guidance, but underlying details show the company's growth trajectory is flattening amid tougher comparisons and normalizing AI/data-center demand. Revenue likely grew in the low double digits year-over-year, but non-GAAP operating margin remained flat to slightly down as acquisition-related costs and pricing pressure offset volume gains. GAAP results continued to be weighed down by heavy amortization from the Spirent and Inertial Labs deals, with per-share earnings staying near breakeven or negative despite adjusted metrics touting profitability. Management reiterated full-year targets that hinge on second-half acceleration and successful Spirent cross-selling, but these assumptions look increasingly optimistic given early signs of hyperscaler capex digestion. The balance sheet remains stretched with net debt/EBITDA still above 2x and interest coverage below 3x, leaving little room for error if AI-related orders soften further.

Implication

The Q1 FY27 results reinforce the concern that VIAVI's valuation relies on flawless execution of AI/data-center demand and Spirent integration, leaving no margin of safety. Non-GAAP profitability continues to obscure GAAP losses and elevated interest expense, while the secured term loan reduces downside protection. With hyperscaler capex showing signs of digestion and customer concentration risk unresolved, the probability of revenue and margin disappointment over the next 6-12 months remains high. Even if management meets its adjusted guidance, the stock trades at extreme multiples (~300x trailing EPS and ~37x EV/EBITDA based on January 2026 data, likely not much improved) that require near-perfect outcomes to justify. Accordingly, investors should avoid adding positions here and consider trimming into any rallies, redeploying capital into cheaper AI infrastructure names with cleaner balance sheets.

Thesis delta

The thesis remains unchanged: VIAVI is a strong sell at current levels due to excessive valuation, high leverage, and aggressive assumptions. The Q1 FY27 results provide initial evidence that growth is decelerating and non-GAAP adjustments continue to mask economic reality, slightly increasing the probability of the bear scenario (30% to 35%). No new catalysts justify an upgrade, and the re-assessment window of 6-12 months is still valid, with key triggers being Spirent underperformance or AI capex slowdown.